Dr. Peter Attia
speaker
5,258 appearances
36 recordings
6 series
first heard Jan 2024
last heard Jun 2025
Dr. Peter Attia’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
And you could argue with a regulatory change in the FDA, if we said greater emphasis on safety to approval, greater emphasis on post-market surveillance for efficacy, we shift this thing a little bit. Now you could say at three years we're trending, you get a provisional approval, and now we're going to follow you.
There's an example like PaxLivid in my mind, you could argue maybe should have been pulled, maybe it wasn't as effective as it looked in the trials. And that doesn't mean they were wrong to approve it because it was any port in a storm. But after the fact, we could have been, oh, you know what? No harm, no foul. It was safe.
And so maybe we do that for oncology.
Exactly. Ongoing.
This is across the board, not just in clinical trials.
I think that that is absolutely correct. On the nursing front, there's a huge demand, obviously. How much of this do you think of absent robotics? So robots can really change the game. I'm not close enough to that. Are you?
Yeah. So I don't know how long until a robot is doing what a nurse is doing. But when you think of medical and chart reconciliation and things like that, is that where you think the greatest opportunity is?
So the Nobel Prize last year was awarded for protein folding, AI-driven analysis. Explain to people why that is significant. How much do you think that particular achievement is going to advance biotechnology and what remains ahead of it as far as even greater molecule selection?
This is how you even- This is figuring out what you're going to do.
Do you think this is the most important thing from a promise perspective that AI has brought to medicine since?
Yeah.
And so what do you think would be the next mega unlock? Would it be on the data front? Would it be a predictive model? How could we shorten a clinical trial by 60%?
You need a good biomarker.
Yeah. There undoubtedly are. There probably are.
Sue, what's your level of optimism or pessimism around liquid biopsies? And do you think that AI can help us with these?
And is this on the sensitivity front? Yeah.
Yeah, I was about to say, do you think the problem is tumors don't shed enough DNA?
I agree with you, by the way. I would add to that PSA in the hands of someone who understands what to do with it. So PSA by itself, pretty bad. PSA density when you know prostate volume and PSA velocity when you have serial measurements starts to become very predictive. So you take a man who has not had a prostate biopsy,
and you stratify his PSA according to PSA density, the ability to predict if he has a Gleason 3 plus 3 or 3 plus 4 or 4 plus 3 is really quite high. It's high. And at least you can then stratify those patients more quickly into a PHI or a 4K and ultimately decide do they need a multi-parametric MRI and you go down that path.
So it's not turnkey and I completely understand why they've said we're going to make no recommendation. I do take comfort in knowing. It's sad to me, but I take comfort in knowing. Too many men are dying of prostate cancer. It should not be the third leading cause of cancer death. It shouldn't. And yet I understand that it's a big ask to get every doctor fully up to speed on the algorithm.
Showing 941–960 of 5,258 · page 48 of 263
← Previous
Next →